Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

About Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $9.8 million
  • Outstanding Shares: 14,619,000
Average Prices:
  • 50 Day Moving Avg: $0.82
  • 200 Day Moving Avg: $2.20
  • 52 Week Range: $0.55 - $3.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.69
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.23 per share
  • Price / Book: 2.86
Profitability:
  • EBIDTA: ($16,970,000.00)
  • Return on Equity: -132.68%
  • Return on Assets: -105.14%
Debt:
  • Current Ratio: 2.29%
  • Quick Ratio: 2.29%
Misc:
  • Average Volume: 613,602 shs.
  • Beta: 0.93
  • Short Ratio: 0.66
 

Frequently Asked Questions for Ritter Pharmaceuticals (NASDAQ:RTTR)

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.24. View Ritter Pharmaceuticals' Earnings History.

Where is Ritter Pharmaceuticals' stock going? Where will Ritter Pharmaceuticals' stock price be in 2017?

5 brokerages have issued twelve-month target prices for Ritter Pharmaceuticals' shares. Their predictions range from $3.50 to $9.00. On average, they anticipate Ritter Pharmaceuticals' stock price to reach $6.10 in the next year. View Analyst Ratings for Ritter Pharmaceuticals.

What are analysts saying about Ritter Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (5/23/2017)
  • 2. Maxim Group analysts commented, "Ritter announced today that at an End of Phase II" meeting has been scheduled with FDA for 3Q17. OK, that’s nice but our concern is that the FDA will not be OK with the excluded data recently discussed." (4/12/2017)

Are investors shorting Ritter Pharmaceuticals?

Ritter Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 955,468 shares, an increase of 35.1% from the April 28th total of 707,192 shares. Based on an average trading volume of 619,510 shares, the short-interest ratio is currently 1.5 days. Currently, 9.0% of the shares of the company are sold short.

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:

  • Ira E. Ritter, Executive Chairman of the Board, Chief Strategic Officer
  • Michael D. Step, Chief Executive Officer, Director
  • Ellen Mochizuki, Vice President - Finance
  • Andrew J. Ritter, President, Founder, Director
  • Noah J. Doyle, Independent Director
  • Matthew W. Foehr, Independent Director
  • Paul V. Maier, Independent Director
  • William M. Merino Ph.D., Independent Director
  • Gerald T. Proehl, Independent Director

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

Who owns Ritter Pharmaceuticals stock?

Ritter Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.41%) and KCG Holdings Inc. (0.91%). Company insiders that own Ritter Pharmaceuticals stock include Andrew J Ritter, Gerald T Proehl, Javelin Venture Partners, LP, Matthew W Foehr and Michael D Step. View Institutional Ownership Trends for Ritter Pharmaceuticals.

Who bought Ritter Pharmaceuticals stock? Who is buying Ritter Pharmaceuticals stock?

Ritter Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including KCG Holdings Inc. and Vanguard Group Inc.. Company insiders that have bought Ritter Pharmaceuticals stock in the last two years include Andrew J Ritter, Gerald T Proehl, Javelin Venture Partners, LP, Matthew W Foehr and Michael D Step. View Insider Buying and Selling for Ritter Pharmaceuticals.

How do I buy Ritter Pharmaceuticals stock?

Shares of Ritter Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of Ritter Pharmaceuticals stock can currently be purchased for approximately $0.67.


MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ritter Pharmaceuticals (NASDAQ:RTTR) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.10 (810.18% upside)

Analysts' Ratings History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Maxim GroupReiterated RatingHoldHighView Rating Details
3/30/2017Chardan CapitalLower Price TargetBuy -> Buy$4.50 -> $3.50HighView Rating Details
3/7/2017AegisReiterated RatingBuyMediumView Rating Details
1/4/2017Rodman & RenshawInitiated CoverageBuy$7.00N/AView Rating Details
12/12/2016Roth CapitalInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Earnings by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Earnings History by Quarter for Ritter Pharmaceuticals (NASDAQ RTTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.38)($0.14)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.35)($0.74)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.50)($0.41)ViewN/AView Earnings Details
8/8/2016Q216($0.34)($0.48)ViewN/AView Earnings Details
5/9/2016($0.32)($0.36)ViewN/AView Earnings Details
3/21/2016Q4($0.34)($0.27)ViewN/AView Earnings Details
11/17/2015Q315($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ritter Pharmaceuticals (NASDAQ:RTTR)
Current Year EPS Consensus Estimate: $-1.6900 EPS
Next Year EPS Consensus Estimate: $-0.9700 EPS

Dividends

Dividend History for Ritter Pharmaceuticals (NASDAQ:RTTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Ownership Percentage: 49.00%
Institutional Ownership Percentage: 9.60%
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Institutional Ownership by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Matthew W FoehrDirectorBuy18,000$0.62$11,160.00View SEC Filing  
5/11/2017Michael D StepCEOBuy13,000$0.62$8,060.00View SEC Filing  
2/27/2017Michael D StepCEOBuy10,000$2.65$26,500.00View SEC Filing  
2/22/2016Andrew J RitterMajor ShareholderBuy6,250$1.60$10,000.00View SEC Filing  
1/8/2016Matthew W FoehrDirectorBuy13,000$1.64$21,320.00View SEC Filing  
1/7/2016Michael D StepCEOBuy27,000$1.48$39,960.00View SEC Filing  
6/24/2015Gerald T ProehlDirectorBuy50,000$5.00$250,000.00View SEC Filing  
6/24/2015Javelin Venture Partners, L.P.Major ShareholderBuy800,000$5.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ritter Pharmaceuticals (NASDAQ:RTTR)
Latest Headlines for Ritter Pharmaceuticals (NASDAQ:RTTR)
Source:
DateHeadline
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Short Interest Update
www.americanbankingnews.com - May 28 at 7:12 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 26 at 9:05 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 23 at 7:18 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Director Matthew W. Foehr Acquires 18,000 Shares
www.americanbankingnews.com - May 18 at 4:54 PM
americanbankingnews.com logo-$0.27 Earnings Per Share Expected for Ritter Pharmaceuticals Inc (RTTR) This Quarter
www.americanbankingnews.com - May 15 at 10:30 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Releases Quarterly Earnings Results, Beats Expectations By $0.24 EPS
www.americanbankingnews.com - May 10 at 4:56 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 9 at 11:36 PM
nasdaq.com logoRitter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-
www.nasdaq.com - May 4 at 12:21 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Getting Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 1:03 AM
streetinsider.com logoRitter Pharma (RTTR) Announces New Patents for its Lactose Intolerance Treatment, RP-G28; Provides an Update on ... - StreetInsider.com
www.streetinsider.com - May 2 at 5:27 PM
finance.yahoo.com logoRitter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3
finance.yahoo.com - May 2 at 5:27 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 10:32 PM
feeds.benzinga.com logoExclusive: Ritter Pharmaceuticals CEO Talks Stock Scare, Indication Niche
feeds.benzinga.com - April 28 at 10:42 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Given News Sentiment Score of 0.07
www.americanbankingnews.com - April 27 at 11:26 PM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 24 at 11:20 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Given News Impact Score of 0.37
www.americanbankingnews.com - April 18 at 5:48 PM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Earning Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 10:23 PM
streetinsider.com logoRitter Pharma (RTTR) Says FDA Agrees to Schedule End of Phase 2 Meeting - StreetInsider.com
www.streetinsider.com - April 12 at 6:22 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - April 12 at 4:36 PM
finance.yahoo.com logoRitter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
finance.yahoo.com - April 12 at 1:21 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Price Target Cut to $3.50 by Analysts at Chardan Capital
www.americanbankingnews.com - April 5 at 10:16 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 6:09 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) PT Lowered to $3.50
www.americanbankingnews.com - March 30 at 8:53 AM
baystreet.ca logoRitter Pharmaceuticals (RTTR) Flails on Study Results
www.baystreet.ca - March 29 at 9:25 PM
finance.yahoo.com logoRitter Pharmaceuticals downgraded by Maxim Group
finance.yahoo.com - March 29 at 9:25 PM
biz.yahoo.com logoRITTER PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 29 at 9:25 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Downgraded by Maxim Group
www.americanbankingnews.com - March 29 at 11:41 AM
nasdaq.com logoFirst Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data
www.nasdaq.com - March 29 at 8:38 AM
finance.yahoo.com logo6:33 pm Ritter Pharmaceuticals announces lactose intolerance treatment RP-G28 demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial; data supports further clinical development (halted)
finance.yahoo.com - March 29 at 12:29 AM
finance.yahoo.com logoRitter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
finance.yahoo.com - March 28 at 7:28 PM
americanbankingnews.com logoRitter Pharmaceuticals' (RTTR) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - March 24 at 11:43 AM
americanbankingnews.com logoRitter Pharmaceuticals' (RTTR) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - March 20 at 4:22 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - March 20 at 1:01 PM
americanbankingnews.com logoMaxim Group Reiterates $5.00 Price Target for Ritter Pharmaceuticals Inc (RTTR)
www.americanbankingnews.com - March 18 at 11:52 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 18 at 3:33 PM
seekingalpha.com logoRitter Pharmaceuticals: The Thesis Has Just Changed Dramatically - Seeking Alpha
seekingalpha.com - March 16 at 8:05 AM
seekingalpha.com logoAvoid Ritter Pharmaceuticals - Ritter Pharmaceuticals (NASDAQ ... - Seeking Alpha
seekingalpha.com - March 14 at 7:05 PM
streetinsider.com logoRitter Pharma (RTTR) Discloses Informational Meeting with FDA to Discuss Development Plans and Phase 2b/3 Trial for Treatment of Lactose Intolerance
www.streetinsider.com - March 13 at 7:21 PM
biz.yahoo.com logoRITTER PHARMACEUTICALS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 13 at 7:21 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Earns Buy Rating from Aegis
www.americanbankingnews.com - March 8 at 7:01 PM
rttnews.com logoWhat Awaits These 10 Biotech Stocks In March?
www.rttnews.com - March 5 at 9:13 AM
finance.yahoo.com logoRITTER PHARMACEUTICALS INC Financials
finance.yahoo.com - March 3 at 7:39 PM
biz.yahoo.com logoRITTER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - February 27 at 4:26 PM
biz.yahoo.com logoRITTER PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - February 27 at 9:27 AM
seekingalpha.com logoSet To Explode: Ritter Pharmaceuticals
seekingalpha.com - February 21 at 5:14 PM
us.rd.yahoo.com logoRitter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
us.rd.yahoo.com - February 14 at 6:05 AM
finance.yahoo.com logoRitter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
finance.yahoo.com - January 30 at 8:51 PM
us.rd.yahoo.com logoRitter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome
us.rd.yahoo.com - January 23 at 7:59 PM
finance.yahoo.com logoRitter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors
finance.yahoo.com - January 17 at 12:18 PM
biz.yahoo.com logoRITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
biz.yahoo.com - January 17 at 12:18 PM

Social

Chart

Ritter Pharmaceuticals (RTTR) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff